Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | — |
Patient took first dose of Vivotif and forgot to take second dose, its been about a week from the first dose; Case reference number US-BN-2024-002159 is a spontaneous case initially received from physician via agency (reference number: USBAV24-1588) on 08-Jul-2024 and concerns a female patient of unknown age. The patient's medical history and concomitant medication were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose and route for unknown indication. As reported, the patient forgot to take second dose and it has been about a week from the first dose (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information was provided. Non-significant case correction performed after internal review for information received on 08-Jul-2024 included company comment correction. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240708-a1e2df to US-BAVARIAN NORDIC A/S-US-BN-2024-002159, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A female patient of unknown age forgot to take second dose and it has been about a week from the first dose, which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unknown age forgot to take second dose and it has been about a week from the first dose, which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.